SpringWorks Therapeutics, Inc. (SWTX) shares plummeted 5.98% in after-hours trading on Tuesday, following reports that German pharmaceutical giant Merck KGaA is in advanced talks to acquire the U.S. cancer and rare diseases drugmaker. The potential acquisition raised concerns among analysts about the deal's profitability impact on Merck.
While the acquisition could bolster Merck's cancer-treatment pipeline, analysts questioned whether it would be accretive from the outset. Equita analyst Davide Marchesin pointed out that SpringWorks is currently loss-making despite generating over 350 million euros in annual revenue. This has led to doubts about the deal's immediate financial benefit for Merck.
The market's reaction to these profitability concerns has caused SpringWorks Therapeutics' stock to plunge in after-hours trading, reflecting investor uncertainty about the potential acquisition's implications for the company's financial performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.